Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kowa Launches Japan PIII Study of Glanatec/Brimonidine Combo for Glaucoma, Ocular Hypertension
February 20, 2020
- Drug Makers in Japan Urging Staffers to Work at Home, Shun Rush-Hour Commuting amid Coronavirus Fears
February 19, 2020
- Japan Pharma Market Logs 1st Growth in 3 Years in 2019, Keytruda Is the Best-Seller: IQVIA
February 19, 2020
- Takeda’s Entyvio SC Form Hits Main Goal in PIII Crohn’s Disease Study
February 18, 2020
- HIV Med Pifeltro Now Available in Japan: MSD
February 18, 2020
- Chugai, Sanofi Wind Up License Deal for Apleway; Kowa to Get MA
February 18, 2020
- ASKA Takes Over Uterine Fibroids Drug Relumina from Takeda
February 18, 2020
- Dovobet Foam Formulation Filed in Japan: LEO Pharma/Kyowa Kirin
February 17, 2020
- Tecentriq-Avastin Combo Filed for HCC in Japan: Chugai
February 17, 2020
- Otsuka’s Pharma Sales Surge as Tolvaptan Grows Six-Fold in North America
February 17, 2020
- Teijin Pharma Set to Boost Partnerships in R&D, Seeking Licensee for Diabetic Nephropathy Drug: President
February 17, 2020
- Eisai Pulls Belviq from US Market after FDA Flags Cancer Risks
February 17, 2020
- Chugai, US Foundation Medicine Team Up with NCC for Blood-Based Genomic Testing
February 17, 2020
- StemRIM to Set Up Collaborative Lab in Osaka University
February 14, 2020
- Mitsubishi Chemical to Rev Up Next-Gen Therapy Biz to Enliven Pharma Unit: Chief
February 14, 2020
- Polatuzumab Vedotin Hits Main Goal in Japan PII for DLBCL: Chugai
February 14, 2020
- Ono Revamps Japan Sales Structure to Gear Up for New Launches
February 13, 2020
- Bayer’s Eylea Effective at Both 12-Week and 16-Week Intervals: PIV Study
February 13, 2020
- Astex’s Novel Cancer Drug Accepted for FDA Review: Otsuka
February 13, 2020
- Xtandi Extends Overall Survival in Non-Metastatic CRPC
February 13, 2020
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…